Methods: A retrospective chart review was performed on consecutive infants screened for
ROP. Infants treated with peripheral retinal ablation, bevacizumab 0.625 mg/0.025 mL, or …

Importance Anti–vascular endothelial growth factor (VEGF) therapies are a novel treatment
option in retinopathy of prematurity (ROP). Data on dosing, efficacy, and safety are …

We report our experience with the use of intravitreal ranibizumab for the treatment of
retinopathy of prematurity (ROP). A retrospective review was performed on 138 consecutive …

Purpose The primary endpoint results from the comparing alternative ranibizumab dosages
for safety and efficacy in retinopathy of prematurity (CARE‐ROP) core study identified …

Purpose To evaluate ocular outcome in premature infants treated with intravitreal
ranibizumab injections for retinopathy of prematurity (ROP) over a period of 3 years …

Purpose: To compare the effect and the treatment outcomes of bevacizumab and
ranibizumab in the treatment of Type 1 retinopathy of prematurity (ROP). Methods: This was …

Purpose To investigate the anatomic outcomes and influencing factors of ranibizumab in the
treatment of retinopathy of prematurity (ROP). Design Retrospective case series. Participants …

Purpose To compare the results of ranibizumab and aflibercept treatment in infants with
treatment-requiring retinopathy of prematurity (ROP) in the posterior zone. Methods In this …

Background Treatment of retinopathy of prematurity (ROP) stage 3 plus with bevacizumab is
still very controversial. We report the outcome of 6 eyes of 4 premature infants with ROP …

Purpose To study the time course of retinopathy of prematurity (ROP) regression and
reactivation after treatment with intravitreal ranibizumab or laser in the ranibizumab …